AK-2024

N/A

Report date: 2025/09/22 13:44:13

Base Information

Drug NameAK-2024
Drug Alias NameAK2024AK-2024BSI-128
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBiosion Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAnhui Anke Biotechnology (Group) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A